"NSCLC - Market Outlook and Competitive Landscape Report 2015 – 2030 "

Report Snapshot:
NSCLC is the most common form of lung cancer, accounting for approximately 85% of all types and subtypes of lung cancer. It grows and spreads more slowly than small cell lung cancer. Early stage disease is associated with uncommon specific symptoms; hence roughly ~50% to 73% of cases are not being diagnosed until the disease is at an advanced stage when the chances for cure or significant patient benefit are limited. Thelansis "NSCLC – Market Insight and Landscape report 2015 - 2030" report provides the detailed therapy area landscape comprises of disease overview, pathogenesis, biomarker specific patient population, country/region specific current treatment practice and market landscape.

Market landscape:
•According to Thelansis the global non-small cell lung cancer (NSCLC) market was estimated at ~$6,925 million in 2015 and expected to reach at ~$ 21,546 million by the end of 2030(15 years of markets projections; four years of historical data, current and eleven years of future market projections).
•Currently, there are ~645K advanced NSCLC patients getting the treatment in G8 countries out of which ~12.5% of patients are treated with targeted therapies and by 2030, this is expected to reach to ~1083K patients getting treated and 19% of the patients on targeted therapies. The current market for advanced NSCLC is at ~$5.13 bn of which the targeted therapies contribute to ~65%. EGFR and ALK are the major biomarkers currently tested in advanced NSCLC having targeted therapies

• Major unmet needs in the advanced NSCLC market are unavailability of targeted therapies for sq. patients, KRAS segment, and resistant patients to 1st line and for other biomarkers

• This market is defined as sales of major branded drugs commonly prescribed for NSCLC patients across the 8MM countries and scaled up to the global level. Just over half of these sales, $2.35 B (46%), were generated in the US, with the 5EU representing the next largest region by sales, estimated at $1.35B (28%). Japan and China contributed the smallest proportions of sales to the global NSCLC market, with 2015 sales of $910M (18%) and $425M (8%), respectively. North America, Asia, and Europe are the major regions reported with a high incidence& diagnosed patient pool, however, the developed nation showed a consistent across reported cases by the decreasing/ plateauing smoking trends and relatively higher diagnosis rates.

Epidemiology and patient segmentation:
• According to Thelansis, globally ~ 1.3 million patients are being diagnosed with non-small cell lung cancer (NSCLC) in 2015 among which 8MM countries are comprised of 77% of the total yearly reported cases. The total diagnosed cases of NSCLC expected to reach at ~$ 2,29 million by the end of 2030(15 years of markets projections; four years of historical data, current and eleven years of future epidemiology projections). Considering the country level prospective USA and China are contributing around ~70% of the total diagnosed patient pool, however in terms of market USA is leading considering the current disease burden and treatment cost. Diagnosed incidence trends are relatively high in the USA and Japan attributed to the lung screening programs and the diagnosis of the lung cancer patients in the early stages – 43% in the US and ~70% in Japan

• For NSCLC, the TNM international staging system is used: T describes the size and location of the primary tumor, N describes the presence and location of nodal metastases, and M refers to the presence or absence of distant metastases. NSCLC is divided into four stages, with further subdivision of stages I-III into A and B subtypes. These stages have important therapeutic and prognostic implications. Patients with stage IIIB and stage IV disease do not benefit from surgery. Patients with stage IIIA disease have locally invasive disease that may benefit from surgery in certain circumstances NSCLC - biomarker level patient segmentation:

NSCLC - biomarker level patient segmentation:
•Molecular epidemiology study of specific biomarker mutations across country level has been given an clear understanding on patient pool across different biomarker targets (EGFR Mutation, ALK Rearrangement, BRAF Mutation, FGFR family Amplification, FGFR3 Amplification, HER2 Mutation, KRAS Mutation, MEK1 Mutation, MET Amplification, MET Protein Expression, NRAS Mutation, PIK3CA Mutation, RET Rearrangement, ROS1 Rearrangement, EML4-ALK Rearrangement, PD- L1 Expression, PDGFR)

Current therapy:
•Regardless of recent advances in therapy, lung cancer remains the leading cause of cancer death in men and women in the United States as well as other developed and developing countries. The propensity for metastatic spread, together with a lack of effective screening measures, contributes to the low cure rate. Non-small cell carcinomas account for approximately 80% of lung cancer cases and include at least three distinct histology: squamous (epidermoid) carcinoma, adenocarcinoma (includes bronchioloalveolar), and large cell (undifferentiated) carcinoma. Overall, current treatments are not considered reasonable for most NSCLC patients, with the possible exception of very early-stage patients. Surgery is the major potentially curative therapeutic option for this disease, primarily for Stage I patients. Adjuvant systemic therapy after surgery in patients with locally advanced or Stage II and IIIA disease has been shown to increase survival compared with surgery alone. Other Stage III patients who might not benefit from the surgery will undergo combined-modality therapy such as chemo-radiotherapy. In advanced-stage of disease, systemic therapy offers modest improvements in median survival, although overall survival is poor.

Emerging therapies
As per Thelansis, based on tumor mutation testing, patients are divided into three subgroups: patients with EGFR-positive mutations, patients with ALK rearrangements and patients who do not show EGFR/ALK mutations or have unknown mutation status. However, the evolution of molecular profiling and the implementation of next-generation sequencing in the evaluation of a patient with advanced NSCLC has currently led to the discovery of targetable alterations in patients who previously had not known actionable targets. As effective treatments are found for novel targets such as HER2, ROS1, RET, BRAF, MET, and others, treatment algorithms are becoming more complex with every passing day

The annual cost of therapy:
•According to the published literature review, NSCLC is one of the expensive tumors in the United States and other developed nations. The worldwide epidemic of NSCLC is a major public health concern, not only because of the enormous loss of life and the great morbidity it causes but also because of the large economic burden it places on health care systems and society in general. Based literature review data, the economic burden of lung cancer will be high in industrial countries where the high incidence of lung cancer and adequate resources enable state-of-the-art care to be given. This economic burden may exceed the capacity of developing countries to provide appropriate evidence-based care. Even wealthy nations are experiencing increasing fiscal constraint which is forcing governments and health care administrators to critically examine the value of health care interventions and the efficiency of health care delivery systems. Based on expenditure data the all direct and indirect medical care costs range $35,000 to $148,750 in the USA

KOL’s Perspective:
• Emerging therapies ultimately need to demonstrate efficacy on long-term clinical outcomes in the patients diagnosed with an advanced stage of the disease condition, which is the major challenge considering efficacy label of the current standard of care

•Approximately 70% of the disease population diagnosed in their advanced stage of the disease, so the diagnosis cost to be brought down so that the population can opt for a random diagnosis

•Major unmet needs in the advanced NSCLC market are unavailability of targeted therapies for sq. patients, KRAS segment, resistant patients to 1stline and for other biomarkers which need to address in coming years of research and development

Payers perspective:
•From the payer’s perspective majorly focused on cost savings as both at public and private payer entities are seeking methods to reduce NSCLC related expenditures. The treatment of lung cancer has changed dramatically. Screening has and will continue to increase cure rates. Molecular profiling, coupled with targeted therapies and the expanding role of immunotherapy, is extending the lives and quality of life of patients with advanced disease. These treatments are so effective that, justifiably, they have frequently been approved based on phase I or II data. Patients are living longer and, although this is desired, improvements in survival outcome have also contributed to unsustainable increases in health care costs. Apart from cost, payers have also concerned the continuous recommendation of services (e.g., therapies or diagnostic tests) that have not demonstrated improvements in the outcomes that matter to patients

As the name depicts Thelansis is specialized in “Therapeutic Landscape Analysis” along with market intelligence and consultancy that supports pharmaceutical, biotechnology, and diagnostics companies to successfully prepare, launch, and commercialize their products. Our Syndicated research reports include Market Insight, Pipeline Insight, Product Insight, Specialized Reports, Indication Outlook, and Market Access Reports.
Our focused therapeutic approach provides our clients with clinical and disease area expertise from an integrated team of academic, medical, and industry specialists of our panel
Ask for our report offerings, and Indication specific sample pages by sharing your email ID with us on,

Sales office:
183 Asylum Street Hartford, CT-06103, US
USA +1 (302) 380-3552

Delivery Office
Thelansis Knowledge Partners
B-1030, C Wing Vrindavan tech village
Marathahalli Outer ring road
Bangalore- 560037
India +91-9899921259

Web:- www.thelansis.com
email:- clientsupport@thelansis.com

This release was published on openPR.